{
    "clinical_study": {
        "@rank": "129663", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, ifosfamide, and\n      cisplatin in treating patients who have metastatic testicular cancer that has recurred\n      following treatment."
        }, 
        "brief_title": "Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer", 
        "completion_date": {
            "#text": "July 2005", 
            "@type": "Actual"
        }, 
        "condition": "Testicular Germ Cell Tumor", 
        "condition_browse": {
            "mesh_term": [
                "Testicular Neoplasms", 
                "Neoplasms, Germ Cell and Embryonal"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the feasibility of combining paclitaxel, ifosfamide, and cisplatin induction\n           in patients with metastatic nonseminomatous germ cell tumor of the testis in first\n           relapse following first line treatment with bleomycin, etoposide, and cisplatin.\n\n        -  Determine the response rates to this regimen in these patients\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive paclitaxel IV over 3 hours and ifosfamide IV and cisplatin IV daily for 5\n      days. Patients with stable or responding disease repeat treatment every 3 weeks for 4\n      courses in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A minimum of 25 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Metastatic nonseminomatous germ cell tumor of the testis\n\n               -  In first relapse following first line treatment with bleomycin, etoposide, and\n                  cisplatin\n\n               -  Biopsy proven germ cell tumor OR\n\n               -  Rising tumor markers (alpha fetoprotein and/or human chorionic gonadotropin)\n\n          -  No brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  16 to 64\n\n        Performance status:\n\n          -  0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Glomerular filtration rate greater than 50 mL/min\n\n        Other:\n\n          -  No other prior malignancy except curatively treated nonmelanomatous skin cancer or\n             superficial bladder cancer\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No prior experimental drugs"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004077", 
            "org_study_id": "CDR0000067286", 
            "secondary_id": [
                "MRC-TIP", 
                "EU-99012"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "ifosfamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Isophosphamide mustard", 
                "Cisplatin", 
                "Ifosfamide", 
                "Paclitaxel"
            ]
        }, 
        "keyword": [
            "stage III malignant testicular germ cell tumor", 
            "recurrent malignant testicular germ cell tumor", 
            "testicular embryonal carcinoma", 
            "testicular choriocarcinoma", 
            "testicular teratoma", 
            "testicular yolk sac tumor", 
            "testicular embryonal carcinoma and teratoma", 
            "testicular embryonal carcinoma and yolk sac tumor", 
            "testicular yolk sac tumor and teratoma", 
            "testicular choriocarcinoma and yolk sac tumor", 
            "testicular choriocarcinoma and embryonal carcinoma", 
            "testicular choriocarcinoma and teratoma"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MRC-TIP"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Cardiff", 
                    "country": "United Kingdom", 
                    "state": "Wales", 
                    "zip": "CF14 2TL"
                }, 
                "name": "Velindre Hospital"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "official_title": "A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors", 
        "overall_official": {
            "affiliation": "Velindre NHS Trust", 
            "last_name": "Malcolm D. Mason, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004077"
        }, 
        "results_reference": {
            "PMID": "15999102", 
            "citation": "Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, Stenning SP, Mason M; MRC Testicular Tumour Working Party. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer. 2005 Jul 25;93(2):178-84."
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical Research Council", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 1996", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2001"
    }, 
    "geocoordinates": {
        "Velindre Hospital": "51.482 -3.179"
    }
}